Robert Stoltz, MD
Ophthalmology · Marietta, GANPI 1275584047
Payments from drug & device makers
Across 651 payments — averaging $5978.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3M
- Apellis Pharmaceuticals, Inc.$294K
- Regeneron$223K
- Novartis$223K
- Janssen Research & Development, LLC$67K
- AbbVie$35K
- plus $72K from 15 others
Across 4 payments — averaging $3147.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$13K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 247 | $2,978,395 |
| Apellis Pharmaceuticals, Inc. | 48 | $294,136 |
| Regeneron | 122 | $223,333 |
| Novartis | 27 | $223,087 |
| Janssen Research & Development, LLC | 14 | $66,508 |
| AbbVie(2 entities) | 49 | $34,542 |
| US Retina LLC | 12 | $28,868 |
| Genentech USA, Inc. | 40 | $16,764 |
| ANI Pharmaceuticals, Inc. | 6 | $16,569 |
| Eyepoint US, Inc. | 6 | $7,080 |
| Regeneron Healthcare Solutions, Inc. | 31 | $1,022 |
| Alcon | 8 | $562 |
| Carl Zeiss Meditec USA, Inc. | 4 | $396 |
| Bausch & Lomb Americas Inc. | 3 | $311 |
| Astellas Pharma US Inc | 9 | $243 |
| Coherus Oncology, Inc. | 10 | $211 |
| Alimera Sciences, Inc. | 9 | $158 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Sandoz | 1 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $30 |
| Biogen | 1 | $24 |
How this compares
$3,892,307 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Marietta
- Lakshmana KooragayalaMarietta$1.4M
- Annal MelethMarietta$446K
- Puneet PandaMarietta$185K
- Rajesh RangarajMarietta$23K
- Dennis MarcusAugusta$9.2M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.